Molecular Response Appoints CEO
This article was originally published in Scrip
Dr Brett Hall, former lead of the oncology translational medicine group at MedImmune (a subsidiary of AstraZeneca) has been appointed chief executive officer of Molecular Response LLC, a privately held molecular diagnostic services and therapeutic target identification company.